New insider activity at NeoGenomics ( (NEO) ) has taken place on May 10, 2025.
In recent transactions, NeoGenomics has seen significant insider buying activity. Director Lynn Tetrault acquired 7,000 shares of NeoGenomics stock, with the purchase valued at $56,910. Additionally, Director Stephen M. Kanovsky purchased 4,000 shares, amounting to a total of $31,120. These transactions highlight a growing confidence in the company’s future prospects.
Recent Updates on NEO stock
In the last 24 hours, NeoGenomics has seen significant adjustments in its stock price targets by multiple analysts due to various financial and market challenges. Piper Sandler, Morgan Stanley, TD Cowen, BofA, and BTIG have all lowered their price targets for NeoGenomics, citing reasons such as a Q1 earnings miss, lower non-clinical revenue, and a lower-than-expected average unit price. Analysts also pointed to a more cautious tone regarding the challenging pharma environment and the company’s aggressive 2025 guidance despite consecutive sales misses. Additionally, the lower revenue guidance for its acquired Pathline business and a shift in the perception of NeoGenomics as a consistent growth business have contributed to the downward revisions. The stock experienced a significant selloff, finishing the day down 34%, reflecting these concerns.
Spark’s Take on NEO Stock
According to Spark, TipRanks’ AI Analyst, NEO is a Neutral.
NeoGenomics presents a mixed investment outlook. The company shows strong revenue growth and strategic initiatives, but faces challenges with profitability, high leverage, and negative cash flow. Technical indicators suggest bearish momentum, while the valuation metrics highlight ongoing losses. Corporate leadership changes and strategic acquisitions provide some positive momentum, but investors should be cautious due to the current financial and market conditions.
To see Spark’s full report on NEO stock, click here.
More about NeoGenomics
YTD Price Performance: -50.70%
Average Trading Volume: 2,072,917
Technical Sentiment Signal: Sell
Current Market Cap: $1.03B